The experiment of intratumor injection with gelatin microsphere containing 131I and mitomycin C (131I-MMC-GM) into implanted hepatoma-22 In mice is reported. Seventy Bal B/C mice were grouped into A, B, C, and D. Intr...The experiment of intratumor injection with gelatin microsphere containing 131I and mitomycin C (131I-MMC-GM) into implanted hepatoma-22 In mice is reported. Seventy Bal B/C mice were grouped into A, B, C, and D. Intratumor injection were given as follows: (A) 131I-MMC-GM, (B) 131I solution; (C) mitomycin C solution; (D) untreated control. The tumor-regression rates of the Group A, B and C as compared to Group D were 58. 7% , 23. 9% and 25. 4%. The average life times of Group A, B, C and were 40. 5, 25. 5, 24. 5 and 17. 1 days. Radioactivity counts in tumors and other organs in group A and B were measured with Y-Counter, which showed that 131I was concentrated in tumors in Group A but it was very low in other organs. The study showed that 131I-MMC-GM is effective and safe anticancer agent, intratumor injection with 131I-MMC-GM will be a promising therapy for the treatment of hepatoma.展开更多
文摘The experiment of intratumor injection with gelatin microsphere containing 131I and mitomycin C (131I-MMC-GM) into implanted hepatoma-22 In mice is reported. Seventy Bal B/C mice were grouped into A, B, C, and D. Intratumor injection were given as follows: (A) 131I-MMC-GM, (B) 131I solution; (C) mitomycin C solution; (D) untreated control. The tumor-regression rates of the Group A, B and C as compared to Group D were 58. 7% , 23. 9% and 25. 4%. The average life times of Group A, B, C and were 40. 5, 25. 5, 24. 5 and 17. 1 days. Radioactivity counts in tumors and other organs in group A and B were measured with Y-Counter, which showed that 131I was concentrated in tumors in Group A but it was very low in other organs. The study showed that 131I-MMC-GM is effective and safe anticancer agent, intratumor injection with 131I-MMC-GM will be a promising therapy for the treatment of hepatoma.
